However, all these mutant-selective and “pan-KRAS” inhibitors target the GDP-bound inactive state of the RAS-GTPase(s) in question and are susceptible to perturbations that drive the cellular equilibrium toward the GTP-bound active state of RAS proteins in tumor cells, e.g., increased upstream RTK signaling. Here, KRAS is linked to neoplasm.